Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients
Condition: Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics Interventions: Drug: Empagliflozin; Drug: olanzapine Sponsor: Tanta University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Empagliflozin | Jardiance | Research | Schizophrenia | SGLT2 Inhibitors | Sodium | Zyprexa